Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

Corey A. Carter, Karen Zeman, Regina M. Day, Patrick Richard, Arnold Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski, Bryan Oronsky

Research output: Contribution to journalArticle

Abstract

Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific "driver" mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, "elephant in the room", is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to "prime" tumors and reverse resistance.

Original languageEnglish (US)
Pages (from-to)40781-40791
Number of pages11
JournalOncotarget
Volume7
Issue number26
StatePublished - 2016
Externally publishedYes

Fingerprint

Epigenomics
Non-Small Cell Lung Carcinoma
Biomarkers
Neoplasms
Therapeutics
Head
Mutation

Keywords

  • Epigenetics
  • Non small cell lung cancer
  • Oncology
  • Resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Carter, C. A., Zeman, K., Day, R. M., Richard, P., Oronsky, A., Oronsky, N., ... Oronsky, B. (2016). Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 7(26), 40781-40791.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. / Carter, Corey A.; Zeman, Karen; Day, Regina M.; Richard, Patrick; Oronsky, Arnold; Oronsky, Neil; Lybeck, Michelle; Scicinski, Jan; Oronsky, Bryan.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 40781-40791.

Research output: Contribution to journalArticle

Carter, CA, Zeman, K, Day, RM, Richard, P, Oronsky, A, Oronsky, N, Lybeck, M, Scicinski, J & Oronsky, B 2016, 'Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies', Oncotarget, vol. 7, no. 26, pp. 40781-40791.
Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N et al. Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget. 2016;7(26):40781-40791.
Carter, Corey A. ; Zeman, Karen ; Day, Regina M. ; Richard, Patrick ; Oronsky, Arnold ; Oronsky, Neil ; Lybeck, Michelle ; Scicinski, Jan ; Oronsky, Bryan. / Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40781-40791.
@article{c2ac7ab2d65349a1a32082af412359ac,
title = "Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies",
abstract = "Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific {"}driver{"} mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, {"}elephant in the room{"}, is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to {"}prime{"} tumors and reverse resistance.",
keywords = "Epigenetics, Non small cell lung cancer, Oncology, Resistance",
author = "Carter, {Corey A.} and Karen Zeman and Day, {Regina M.} and Patrick Richard and Arnold Oronsky and Neil Oronsky and Michelle Lybeck and Jan Scicinski and Bryan Oronsky",
year = "2016",
language = "English (US)",
volume = "7",
pages = "40781--40791",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

AU - Carter, Corey A.

AU - Zeman, Karen

AU - Day, Regina M.

AU - Richard, Patrick

AU - Oronsky, Arnold

AU - Oronsky, Neil

AU - Lybeck, Michelle

AU - Scicinski, Jan

AU - Oronsky, Bryan

PY - 2016

Y1 - 2016

N2 - Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific "driver" mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, "elephant in the room", is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to "prime" tumors and reverse resistance.

AB - Like Chinese boxes nesting inside each other, the classification of non-small cell lung cancer (NSCLC) is subdivided into smaller and smaller subtypes on the basis of histological and molecular attributes. The latter characterizes NSCLC by its molecular alterations and the identification of inhibitors that target these cancer-specific "driver" mutations. Despite the initial promise of precision-guided therapies to inhibit a finer and finer array of molecular subcategories, despite even the curative potential of immunotherapeutic checkpoint blockade, in particular, casualties still abound and true clinical success stories are few and far between; the ever-present, if sometimes unmentioned, "elephant in the room", is the acquisition of resistance, which, sooner or later, rears its ugly head to undermine treatment success and shorten survival. Emerging data suggests that epigenetic therapies are able to reprogram the aberrant tumor-associated epigenome and 'tame the beast of resistance', thereby prolonging survival. This article reviews the role of epigenetic dysregulation in NSCLC, explores PFS2 as a possible surrogate endpoint, briefly mentions possible biomarkers and highlights combinatorial treatment epigenetic strategies to "prime" tumors and reverse resistance.

KW - Epigenetics

KW - Non small cell lung cancer

KW - Oncology

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=84982994746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982994746&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84982994746

VL - 7

SP - 40781

EP - 40791

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -